The Efficacy of Tocotrienol Rich Fraction for Liver Protection in Adult Patients With Alcoholic Fatty Liver Disease (AFLD)

This clinical study aims to explore the potential liver-protective effects of palm tocotrienol-rich fraction (a form of Vitamin E) in adults with alcoholic fatty liver disease (AFLD). A total of 26 participants aged 18 to 65 years with AFLD will be randomly assigned to receive either tocotrienol (200 mg twice daily) or a placebo for six months. Throughout the study, participants will undergo regular liver health assessments including blood tests, FibroScan, and FibroTest, alongside evaluations of oxidative stress and inflammation markers. The study aims to determine whether tocotrienol can help improve liver function and reduce alcohol-related liver damage. Findings from this trial may provide valuable evidence for future clinical studies and highlight the potential of Malaysian palm-based tocotrienol as a natural, supportive approach to liver health.

NCT Number	NCT07466485
Lead Sponsor	Universiti Kebangsaan Malaysia Medical Centre Collaborators: Malaysia Palm Oil Board, Hovid Berhad
Conditions	Alcoholic Fatty Liver Disease
Enrollment	26 participants
Start Date	2026-05-02
Primary Completion	2026-11-10 (estimated)
Study Completion	2027-02-15 (estimated)
Updated on ClinicalTrials.gov	2026-04-29